The study was approved by the National Bioethics Committee of Iceland and The Icelandic Data Protection Authority and adhered to the tenets of the Declaration of Helsinki. All participants signed informed consent. The study was a prospective, nonrandomized clinical trial.
Eligible patients were recruited from our glaucoma clinic (Augnlæknar Reykjavíkur, Reykjavik, Iceland). The inclusion criteria included a diagnosis of POAG, age 40 years or older, and a history of increased IOP. Patients receiving antihypertensive medication for elevated systemic blood pressure and those with cataracts were not excluded because of the prevalence of these conditions in the age group studied. However, patients with other ocular diseases were excluded as were patients with other systemic diseases, such as diabetes. In all, 31 patients were enrolled into the study.
The right eye in each patient was studied except in the case of low image quality from the oximeter, in which case oxygen saturation in the left eye was measured. Clinical data of the study group are shown in
Table 1.
Noninvasive spectrophotometric oximetry was performed on the same day as the ophthalmologic evaluations. The oximeter (
Fig. 1 (Oxymap ehf., Reykjavik, Iceland) consists of a fundus camera (CR6–45NM; Canon Inc., Tokyo, Japan) with an attached beam splitter (Multispec Patho-Imager; Optical Insights, Tucson, AZ.) and a digital camera (SBIG ST-7E; Santa Barbara Instrument Group, Santa Barbara, CA). The instrument (described in detail elsewhere
25 ) delivers two images at two different wavelengths: 605 nm, which is sensitive to oxygen saturation, and 586 nm, which is not sensitive to oxygen saturation. A software algorithm automatically calculates the optical density (OD) of retinal vessels from the two acquired images according to the equation OD = log (
I 0/
I), where
I 0 is light reflected by the background to the side of the vessel and
I is the light reflected from the vessel. The ratio of the OD at 605 nm and the OD at 586 nm is approximately inversely related to hemoglobin oxygen saturation. Measurements were made in first- and second-degree retinal arterioles and venules inferior and superior to the optic nerve head. All measurements were performed in the dark, but with infrared aiming light. Each subject spent 2 minutes in darkness before oximetry.
Pupils were dilated with 1% tropicamide (Mydriacyl; S.A. Alcon-Couvreur N.V., Puurs, Belgium). When needed, this was supplemented with 10% phenylephrine hydrochloride (AK-Dilate; Akorn Inc., Buffalo Grove, IL) and 0.5% proparacaine hydrochloride (Alcaine; S.A., Alcon-Couvreur N.V.).
All visual field testing was performed using a perimeter (Octopus 123; Interzeag AG, Schlieren, Switzerland) using program G1. For 22 patients, the visual field tests were performed on the same day as oximetry. For nine patients, perimetry was not performed on the same day as oximetry, but no more than 5 months elapsed before oximetry was performed. We required the reliability factor of the visual field to be under 15%; one patient was excluded because of a frequency of false-positive answers, resulting in a reliability factor >15%. Because false-negative answers represent the status of the eye rather than the status of the patient,
28,29 they did not count as an exclusion factor. Visual fields with a mean defect ranging from −2 dB to 2 dB were defined as good visual fields, and visual fields with a mean defect equal to or exceeding 10 dB were defined as poor visual fields.
IOP was measured using Goldmann applanation tonometry mounted on a slit lamp (Haag-Streit BQ 900; Haag-Streit International, Köniz, Switzerland) on the day oximetry was performed. Systolic and diastolic blood pressure (SP and DP, respectively) were measured using an automatic sphygmomanometer (HEM-705CP; Omron, Kyoto, Japan). Mean arterial pressure (MAP) was calculated as MAP = ⅔ DP + ⅓ SP. Mean ocular perfusion pressure was calculated as ⅔ MAP-IOP. Finger oximetry was performed using a pulse oximeter (Biox 3700; Ohmeda, Boulder, CO) with the probe placed on the index finger of the right hand.
P
o 2 was calculated from saturation values with an online calculator (
http://www.ventworld.com/resources/oxydisso/oxydisso.html) that uses a previously published method.
30,31 Calculations were based on the hemoglobin dissociation curve, and standard conditions were assumed for T = 37°C and P
co 2 = 40 mm Hg. The pH level for arterial blood was assumed to be 7.4. The pH level for venous blood was assumed to be 7.3.
32 –35 At high oxygen saturation values, the dissociation curve flattens, and calculated P
o 2 values higher than 90 mm Hg were recorded as >90 mm Hg.
Statistical analysis was performed (PRISM, version 5.01; GraphPad Software Inc., La Jolla, CA). Pearson's correlation was used to detect correlations between mean defect and oxygen saturation levels. Unpaired Student's t-test was used to detect a difference between two groups and their saturation levels. For both analyses, P ≤ 0.05 was considered statistically significant.